DNMT inhibitors like 5-azacytidine and decitabine (5-aza-2′-deoxycytidine) have already been approved by the FDA for the treatment of acute myeloid leukemia and myelodysplastic syndrome when used in combination with conventional therapies [54]. Here, DNMT1 is linked to myelodysplastic syndrome.